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Abstract
Background: Membrane-associated ATP binding cassette (ABC) transport proteins hydrolyze ATP in order to
translocate a broad spectrum of substrates, from single ions to macromolecules across membranes. In humans,
members from this transport family have been linked to drug resistance phenotypes, e.g., tumour resistance by
enhanced export of chemotherapeutic agents from cancer cells due to gene amplifications or polymorphisms in
multidrug resistance (MDR) protein 1. Similar mechanisms have linked the Plasmodium falciparum PfMDR1 transporter
to anti-malarial drug resistance acquisition. In this study, the possible involvement of two related MDR proteins, PfMDR2
and PfMDR5, to emerging drug resistance is investigated by a reverse genetics approach.
Methods: A homologous double crossover strategy was used to generate P. falciparum parasites lacking the Pfmdr2
(PfΔmdr2) or Pfmdr5 (PfΔmdr5) gene. Plasmodium lactate dehydrogenase activity was used as read-out for sensitivity to
artemisinin (ART), atovaquone (ATO), dihydroartemisinin (DHA), chloroquine (CQ), lumefantrine (LUM), mefloquine (MQ),
and quinine (QN). Differences in half maximal inhibitory concentration (IC50) values between wild type and each mutant
line were determined using a paired t-test.
Results: Both PfΔmdr2 and PfΔmdr5 clones were capable of asexual multiplication. Upon drug exposure, PfΔmdr2
showed a marginally decreased sensitivity to ATO (IC50 of 1.2 nM to 1.8 nM), MQ (124 nM to 185 nM) and QN (40 nM
to 70 nM), as compared to wild type (NF54) parasites. On the other hand, PfΔmdr5 showed slightly increased sensitivity
to ART (IC50 of 26 nM to 19 nM).
Conclusion: Both Pfmdr2 and Pfmdr5 are dispensable for blood stage development while the deletion lines show
altered sensitivity profiles to commonly used anti-malarial drugs. The findings show for the first time that next to
PfMDR2, the PfMDR5 transport protein could play a role in emerging drug resistance.
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Background
ATP binding cassette (ABC) transporters are membrane-
bound proteins that translocate a wide variety of substrates,
including sugars, peptides, inorganic ions, proteins, and
drugs across membranes by consumption of ATP, even
against high concentration gradients [1,2]. These transport
proteins either consist of two domains, a transmembrane
domain with six membrane-spanning α-helices and a
nucleotide-binding domain (half transporter) or four
domains, two from each of the above alternating each
other (full transporter). The nucleotide-binding domain is
characteristic for ABC transport proteins and contains
conserved Walker A and B motifs to bind ATP and an
ABC signature sequence [3,4]. It is well described that the
human P-glycoprotein, a member of the B subfamily of
ABC transport proteins, also known as multidrug resist-
ance (MDR) proteins, provides tumour resistance to che-
motherapeutics by extrusion of these substances from
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cancer cells due to MDR1 gene amplifications or poly-
morphisms [2,5-7]. Based on sequence identity, Plasmo-
dium falciparum has been shown to contain 16 ABC
family members in its genome [8], some of which also
play important roles in drug resistance development in
this parasite.
Plasmodium falciparum causes the most dangerous
type of malaria, a life-threatening disease that affected
198 million individuals with an estimated 584,000 fatal-
ities in 2013, especially African children under five [9].
Although treatable, recent reports showed emerging re-
sistance as measured by prolonged parasite clearance
times against artemisinin, the fast-acting drug in the
first-line artemisinin-based combination therapy (ACT),
on the Thai-Cambodian border and in Western Cambodia
[10,11]. Whereas mutations in the K13-propeller have
been identified as molecular markers for increased para-
site half-life, additional loci involved in artemisinin re-
sistance are yet to be discovered [12]. Furthermore,
amplification of and polymorphisms in the P. falcip-
arum mdr1 and mrp1 genes have been associated with,
e.g., artemisinin, chloroquine, lumefantrine, mefloquine,
and quinine resistance [13-18]. In addition, polymor-
phisms and differential Asn-repeat lengths found in
Pfmdr6 were shown to alter drug sensitivity to artesu-
nate and piperaquine [19-22], while a single mutation in
the heavy metal transporting PfMDR2 [23] was linked
to in vitro pyrimethamine resistance, which however,
depended on dhfr mutation status [24]. These findings
show an important role for ABC transport proteins in
P. falciparum drug resistance acquisition. Although the
contribution of the MDR family in emerging drug re-
sistance seems evident, as of yet no studies have
assessed the effect of Pfmdr deletion lines on altered
drug sensitivity.
Here, using a reverse genetics approach, both Pfmdr2
and Pfmdr5 were targeted for gene deletion. Subsequently,
the involvement of two P. falciparum genes, Pfmdr2 and
Pfmdr5, on drug sensitivity to seven well-established anti-
malarial drugs, including artemisinin (ART), atovaquone
(ATO), dihydroartemisinin (DHA), chloroquine (CQ),
lumefantrine (LUM), mefloquine (MQ), and quinine
(QN), belonging to four different drug classes (4-amino-
quinolines, artemisinins, aryl-amino alcohols, and naph-
toquinones), was studied [25].
Methods
Parasite cultivation
Plasmodium falciparum wild type (NF54) and mutant
lines PfΔmdr2 and PfΔmdr5 were cultured in a semi-
automated system as described previously [26,27]. Briefly,
parasites were grown in vitro in 5% haematocrit in RPMI
medium supplemented with human serum (complete
medium), which was changed twice daily. Human red
blood cells were refreshed weekly and obtained from
the Dutch national blood bank (Sanquin, Nijmegen).
Generation and genotyping of PfΔmdr2 and PfΔmdr5 parasites
Plasmodium falciparum mdr2 and mdr5 genes were sta-
bly deleted according to a homologous double crossover
strategy [28,29]. Deletion constructs were based on the
reported pHHT-FRT-(GFP)-Pf52 construct in which the
homologous regions were replaced with mdr2 and mdr5
target regions (TRs), respectively [30]. These regions were
generated by amplifying P. falciparum NF54 genomic
DNA (gDNA) using PfuUltra II Fusion HS DNA Polymer-
ase (Bio-Connect B.V., Huissen, The Netherlands) with
primers (P) P9 and P10 for the 5′ target region and
primers P11 and P12 for the 3′ TR of mdr2, respectively.
Similarly, primers P13-P16 were used to generate TRs for
mdr5 (Additional file 1: Table S1). Following TOPO TA
subcloning (Life Technologies Europe B.V., Bleiswijk, The
Netherlands) of the amplified TRs, these were validated by
restriction digestion and sequencing. Then, 5′ and 3′ TRs
from each mdr gene were cloned in the pHHT-FRT-
(GFP)-Pf52 construct using BssHII plus BsiWI and XmaI
plus NheI restriction enzymes, respectively. This resulted
in two deletion constructs, pHHT-FRT-(GFP)-Pfmdr2 and
pHHT-FRT-(GFP)-Pfmdr5. Transfection and selection
were performed as previously described [30], resulting in
two mdr mutant lines. Both lines were subsequently trans-
fected with the pMV-FLPe construct in order to excise
heterologous DNA (hdhfr::gfp selectable marker) flanked
by flippase recognition target (FRT) sites using enhanced
flippase (FLPe) recombinase [30]. Following limiting dilu-
tion, two cloned mutant lines, PfΔmdr2 and PfΔmdr5
were derived for downstream analysis.
Genotype analysis of the parasite mutants was per-
formed using Expand Long Range dNTPack (Roche
Diagnostics Nederland B.V., Almere, The Netherlands)
(LR-PCR). Mixed asexual blood stage gDNA from wild type
and deletion parasites was isolated using the QIAamp DNA
Blood Mini Kit (Qiagen N.V., Venlo, The Netherlands).
Primers P1 and P2 plus P5 and P6 (Additional file 1:
Table S1) designed to flank the 5′ and 3′ TRs for mdr2
and mdr5, respectively, were used to analyse wild type and
mutant DNA using LR-PCR for correct double homolo-
gous crossover integration. The LR-PCR started with an
initial denaturation at 94°C for 5 min, followed by 35 cycles
of denaturation at 94°C for 30 sec, annealing at 43.5-50°C
(43.5°C for wild type and mutant mdr2, 46°C for wild type
mdr5 and 50°C for mutant mdr5) for 30 sec, elongation
at 60°C for 15 min [31] and a final elongation step at
62°C for 15 min. An additional intra-exonic PCR was
performed on gDNA using primers P3 and P4 and P7
and P8 designed within the gene exon of both mdr
genes (Additional file 1: Table S1). Briefly, gDNA from
wild type and mutant lines was isolated as described
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above and amplified using Taq DNA polymerase (Life
Technologies Europe B.V., Bleiswijk, The Netherlands).
Denaturation at 94°C for 2 min was followed by 40
cycles of denaturation at 94°C for 15 sec, annealing at
52°C for 45 sec and elongation at 60°C for 30 sec,
followed by a final elongation step at 60°C for 2 min.
Anti-malarial sensitivity assays
ART, ATO, CQ, DHA, LUM, MQ, and QN were all pur-
chased from Sigma-Aldrich Chemie B.V. (Zwijndrecht,
The Netherlands). ART and QN were dissolved in metha-
nol, ATO, DHA, LUM, and MQ were dissolved in DMSO,
CQ was dissolved in complete medium (described above)
and serial dilutions of all drugs were stored at −20°C and
thawed prior to use. Anti-malarial sensitivity assays were
performed in at least three independent consecutive ex-
periments using a slightly modified Plasmodium lactate
dehydrogenase (pLDH) method as described previously
[32]. In short, 50 μL of serially diluted drugs was added to
black, clear-bottom, 96-well, cell culture plates (Greiner
Bio-One B.V., Alphen a/d Rijn, The Netherlands) in tripli-
cate (duplicate for the 0 concentrations). Then, 50 μL
mixed asexual stage wild type (NF54) and mutant para-
sites (2.5% parasitaemia in 1% final haematocrit) was
added to each drug-containing well. Following incubation
for 72 hrs at 37°C in a candle jar [33], the 96-well plates
were frozen for at least 3 hrs at −20°C. After thawing the
plates, parasite pLDH activity was measured by adding
70 μL of freshly made reaction mix (286 mM sodium
L-lactate (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands), 286 mM 3-acetyl pyridine adenine
dinucleotide (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands), 357.5 μM resazurin (Sigma-Aldrich
Chemie B.V., Zwijndrecht, The Netherlands), 5.66 U/mL
diaphorase (Worthington Biochemical Corp., Lakewood,
NJ, USA), 1.4% Tween-20 (Sigma-Aldrich Chemie B.V.,
Zwijndrecht, The Netherlands), 20 mM Tris–HCl pH 8.0)
to each well. Next, the plates were incubated in darkness
for 30–60 min and absorbance was measured at 590 nm
after excitation at 530 nm using a Synergy 2 Multi-
Mode Microplate Reader (Bio-Tek, Bad Friedrichshall,
Germany). The logarithm of half maximal inhibitory
concentration (logIC50) values were determined by non-
linear regression fitting of dose–response inhibition
curves with variable slopes using GraphPad Prism ver-
sion 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).
For each anti-malarial drug, Hill slopes were fixed to
the average of all non-ambiguous slopes for each mdr
mutant and their wild type control. Comparisons for
significant differences between the obtained logIC50-
values of wild type and mutant groups were carried out by
a paired t-test. Finally, the plotted curves represent the
combined averages of each individual anti-malarial assay
per line, where the top of each curve fit was set to 100%.
Results
Plasmodium falciparum mdr2 and mdr5 are dispensable
for asexual blood stage multiplication
Possible drug resistance association of two P. falciparum
MDR transport proteins, PfMDR2 and PfMDR5, were
studied by a reverse genetics approach. In order to gen-
erate stable Pfmdr2 and Pfmdr5 gene deletion asexual
stage mutants, a homologous double crossover strategy
was used [28,29] with the pHHT-FRT-(GFP)-Pfmdr2 and
pHHT-FRT-(GFP)-Pfmdr5 deletion constructs (Figure 1A
and B). Heterologous DNA including the hdhfr::gfp select-
able marker flanked by FRT sites was subsequently removed
from the mutant parasites using FLP-mediated sequence ex-
cision [30]. Diagnostic long-range PCR (LR-PCR) reactions
were performed to validate the lines lacking the en-
dogenous Pfmdr2 (PfΔmdr2) and Pfmdr5 (PfΔmdr5)
genes. LR-PCR using primers (P) P1 and P2 flanking the
target regions resulted in the expected amplification
products of 5,571 bp and 2,553 bp for gDNA from NF54
wild type and PfΔmdr2 parasites, respectively (Figure 1C).
Similarly, wild type and PfΔmdr5 gDNA was amplified
using P5 and P6, producing amplicons of 5,028 bp and
2,303 bp, respectively (Figure 1C). To ensure that neither
of the wild type genes was still present, intra-exonic PCRs
were performed using P3 and P4 plus P7 and P8 within
the exons of Pfmdr2 and Pfmdr5, respectively. For the
Pfmdr2 gene, PCR amplification of wild type gDNA re-
sulted in a 92 bp product, whereas no amplification was
seen in the PfΔmdr2 line as expected (Figure 1D). Analo-
gously, a 96 bp product was generated from wild type
gDNA using the Pfmdr5 primers, unlike PfΔmdr5 gDNA
where no product could be obtained (Figure 1D). Both
generated mutants showed unaltered morphology and
growth rate (data not shown). Combined, these results
show that both Pfmdr2 and Pfmdr5 genes were success-
fully deleted and not required for P. falciparum asexual
blood stage multiplication.
Both Pfmdr2 and Pfmdr5 modulate Plasmodium falciparum
drug susceptibility
To assess whether Pfmdr2 and Pfmdr5 could play a role
in P. falciparum susceptibility to anti-malarial drugs,
both PfΔmdr2 and PfΔmdr5 mutants were subjected to a
panel containing seven drug compounds (ART, ATO, CQ,
DHA, LUM, MQ, and QN) and altered sensitivity to any
of the drugs was assessed compared to wild type (NF54).
No difference in sensitivity to ART, CQ, DHA, and LUM
was observed for the PfΔmdr2 mutant (Figure 2A, C-E).
Upon deletion of Pfmdr2, sensitivity to ATO (n = 7) mar-
ginally decreased, as is shown by an increase in average
IC50 from 1.2 nM (95% CI 0.9–1.5 nM) (wild type) to 1.8
nM (95% CI 1.3–2.5 nM) (PfΔmdr2, p = 0.017) (Figure 2B).
Furthermore, PfΔmdr2 parasites also became less sensitive
to MQ (n = 6) and QN (n = 4), both belonging to the
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aryl-amino alcohol class of anti-malarials [25]. For both
drugs, sensitivity was reduced significantly, with an average
IC50 of 124 nM (95% CI 86–180 nM) against MQ in wild
type to 185 nM (95% CI 145–234 nM) in PfΔmdr2 para-
sites (p = 0.004), and an IC50 of 40 nM (95% CI 27–60 nM)
in wild type to 70 nM (95% CI 57–85 nM) in PfΔmdr2 par-
asites for QN (p = 0.022) (Figure 2F-G). No difference in
sensitivity to ATO, CQ, DHA, LUM, MQ, and QN was de-
tected for the PfΔmdr5 mutant (Figure 2B-G). In contrast,
for ART (n = 5), the IC50 of PfΔmdr5 mutant parasites de-
creased slightly but significantly (p = 0.046) from an aver-
age of 26 nM (95% CI 19–36 nM) in wild type to 19 nM
(95% CI 14–27 nM) in PfΔmdr5 parasites, highlighting
ART as being the single compound showing an increase in
sensitivity following mdr deletion in this study (Figure 2A).
Discussion
Increasing P. falciparum resistance to anti-malarial drugs
is a major threat for effective malaria treatment. For this
reason, it is important to unravel proteins and mecha-
nisms that contribute to drug resistance. While involve-
ment of the PfMDR1 transport protein in P. falciparum
drug resistance is evident, little is known about contri-
bution of other P. falciparum MDR members. Thus,
using a reverse genetics approach, the aim of this study
was to determine whether PfMDR2 and PfMDR5 could
play a role in decreased drug sensitivity development
using a panel of seven anti-malarials. Both PfΔmdr2 and
PfΔmdr5 mutant lines were able to complete asexual
development, highlighting that during this stage the
transport proteins are dispensable for parasite viability.
It is hypothesized that PfΔmdr2 and PfΔmdr5 become
more susceptible to the tested anti-malarials if: i) the
anti-malarial is a substrate for the wild type transporter;
and, ii) the wild type MDR protein is located on the
plasma membrane, which in the case of mutant lines
would result in accumulation of the compounds within
the parasite followed by its demise.
In contrast to the hypothesis above, deletion of
P. falciparum mdr2 induced some decrease in sensitivity
to the anti-malarials ATO, MQ and QN. As PfMDR2 has
been reported to localize to the plasma membrane of
the parasite [34], deleting this protein would result in
accumulation of substrate anti-malarials within the
Figure 1 Pfmdr2 and Pfmdr5 deletion strategy and genotyping of the mutants. (A + B) Schematic diagrams showing the Pfmdr2 and
Pfmdr5 gene deletion strategy. Following separate transfection and positive selection on WR99210, the pHHT-FRT-(GFP)-Pfmdr2 or pHHT-FRT-
(GFP)-Pfmdr5 construct integrated into either the 5′ or 3′ target region (TR) in the NF54 wild type locus. Upon negative selection with 5-
fluorocytosine, the mdr gene (black arrow) was replaced by the positive selection cassette harbouring the hdhfr::gfp fusion gene (green arrow)
flanked by FRT sites (blue triangles) (PfΔmdr2gfp or PfΔmdr5gfp). This fusion gene was subsequently removed by FLPe-mediated excision upon pMV-
FLPe transfection resulting in two mdr deletion lines, PfΔmdr2 and PfΔmdr5. cam: calmodulin; hdhfr::gfp: human dihydrofolate reductase fused to
green fluorescent protein; hrp: histidine rich protein; hsp: heat shock protein; mdr: multi-drug resistance; Scfcu: Saccharomyces cerevisiae cytosine
deaminase/uracil phosphoribosyl-transferase; Pbdt: Plasmodium berghei dhfr terminator; FRT: flippase recognition target; P: primer; TR: target
region. Diagnostic long range (C) and intra-exonic (D) PCRs performed on genomic DNA from wild type (NF54, lane 1 or lane 3) and mutant
(PfΔmdr2, lane 2 or PfΔmdr5, lane 4) lines, successfully confirmed deletion of Pfmdr2 and Pfmdr5 in which heterologous DNA was removed.
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parasite, leading to an increased sensitivity phenotype.
However, besides plasma membrane association, PfMDR2
expression on the food vacuole has also been proposed
[23,35]. MQ and QN are incorporated into growing
haemozoin polymers within the food vacuole [36] and
therefore are toxic to the parasite, hence, deletion of
PfMDR2 might prevent accumulation of these drugs in
the digestive vacuole, resulting in decreased sensitivity
of PfΔmdr2 to MQ and QN as shown here. In contra-
diction to these results, it has been reported that MQ and
potentially QN prevent uptake of host cell hemoglobin by
inhibiting endocytosis [37,38] and therefore it may be
advantageous for P. falciparum to sequester these drugs in
the food vacuole [39]. However, at this stage, it is unclear
whether MQ and QN accumulation in the food vacuole is
indeed affected by Pfmdr2 deletion. While LUM belongs
to the same drug class as MQ and QN [25], the PfΔmdr2
mutant does not show the same trend in sensitivity to
LUM as compared to the latter drugs. This might indicate
that LUM is not a substrate for Pfmdr2 or (less likely)
it has a different site of action, which currently is
undetermined. ATO exerts its anti-malarial activity by inhi-
biting the parasite’s oxygen consumption in mitochondria
[40]. While mitochondrial localization of PfMDR2 has not
been shown, further research may link PfMDR2 deletion to
decreased ATO sensitivity. Moreover, it would be interest-
ing to test several drug combinations to observe synergistic
effects. These findings indicate that PfMDR2 may be in-
volved in drug sensitivity either directly or indirectly via
drug substrates.
Upon deletion of P. falciparum mdr5, only sensitivity to
ART was altered. In concordance with the hypothesis, para-
sites lacking PfMDR5 became slightly more sensitive to
ART, suggesting that this drug is a possible substrate for the
PfMDR5 transport protein. As PfMDR5 has previously been
shown to localize to the parasite’s plasma membrane [41],
lacking this transport protein could lead to an accumulation
of ART in the parasite, hence, resulting in increased sensitiv-
ity. On the contrary, there was no difference in sensitivity
for PfΔmdr5 versus wild type parasites to DHA, the active
metabolite of artemisinin derivatives [42], highlighting a
possible subtle difference in substrate specificity.
Figure 2 Anti-malarial sensitivity assay of wild type and Pfmdr mutant parasites using seven drugs. Dose–response inhibition curves
showing sensitivity of wild type (NF54), and P. falciparum mdr mutant (PfΔmdr2 and PfΔmdr5) parasites to ART (A), ATO (B), CQ (C), DHA (D),
LUM (E), MQ (F) and QN (G) were plotted with fixed Hill slopes. All assays were repeated at least three times in triplicates in order to determine
significant differences by a paired t-test between the obtained logIC50-values of wild type and mutant groups.
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Conclusions
Plasmodium falciparum does not require PfMDR2 and
PfMDR5 to progress through the asexual multiplication
cycle. Additionally, deletion of PfMDR2 resulted in a
minor decreased sensitivity phenotype to ATO, MQ and
QN. Therefore, P. falciparum might increase its resist-
ance to these anti-malarials by modulating PfMDR2 in
order to prevent these drugs from reaching their pro-
posed target sites. Moreover, the PfMDR5 deletion mu-
tant became slightly more sensitive upon exposure to
ART, suggesting that over-expression or enhanced activ-
ity of this protein might contribute to ART resistance.
Additional file
Additional file 1: Table S1. Diagnostic long-range primers, intra-exonic
primers and targeting construct primers.
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